Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Clinical trial NCT07498335 · RECRUITING

Trial details

NCT number: NCT07498335
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Berger Disease Bergers Disease IgA Nephropathy Immunoglobulin A Nephropathy Primary IgAN Nephritis IgA Type, Nephropathy IgA Type

Start date: 2026-08-26
Primary completion: 2031-09-15
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.